Development direction of pharmaceutical intermediates industry

The so-called pharmaceutical intermediates are actually some chemical raw materials or chemical products used in the pharmaceutical synthesis process This kind of chemical product does not need the production license of drugs It can be produced in ordinary chemical plants As long as it reaches some levels, it can be used for the synthesis of drugs After nearly 30 years of development, the pharmaceutical intermediates industry in China has developed from a small branch of the chemical industry to a new industry with a production value of billions of yuan, and its competition has become more and more In the early stage of industry development, due to the small investment and high rate of return, pharmaceutical intermediate enterprises have mushroomed, especially in Zhejiang Huangyan, Taizhou, Nanjing Jintan, Shijiazhuang, Jinan, northeast and other regions with favorable conditions for the development of pharmaceutical intermediates At present, the limited production of new drugs in the market makes it more and more difficult to develop new products in the pharmaceutical intermediates industry The competition of traditional products is more and more fierce, and the profits of the pharmaceutical intermediates industry are declining rapidly 1 Improve the technology, save the cost, the process route of pharmaceutical intermediates is long, the reaction steps are many, the use of solvents is large, and the potential of technology improvement is great For example, the raw materials with lower value can be used to replace the raw materials with higher value, such as using instead of liquid bromine in the production of aminothiaxamic acid, using ammonium thiocyanate instead of potassium (sodium) thiocyanate in the production, etc.; using a single solvent instead of different solvents in the reaction process to recover the alcohols generated by hydrolysis of ester products, etc 2 Forming its own characteristic products has a great influence in the industry 3 Extend the industrial chain to the upstream and downstream, transfer the main raw materials used by oneself to self production, which can further reduce the cost, and for some special raw materials, it can play a role in avoiding the monopoly of key raw materials Extending down to synthesize APIs directly from pharmaceutical intermediates can further improve the added value of products and sell products directly to pharmaceutical companies However, the investment in the downstream extension is relatively large, and the production technology requirements are relatively high, and good relations should be maintained with the manufacturers of API.